All In Biotech

Drug Trial Radar · NCT06964113

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Jun 11, 2025

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Eisai Korea Inc.Eisai
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.

Conditions

  • Ulcerative Colitis

Interventions

  • Filgotinib MaleateDrug

    Administered as oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Remission at Week 10 or 22Time frame: At Week 10 or 22

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Site #13

    Busan, South Korea

  • Eisai Site #15

    Busan, South Korea

  • Eisai Site #8

    Busan, South Korea

  • Eisai Site #6

    Daegu, South Korea

  • Eisai Site #2

    Daejeon, South Korea

  • Eisai Site #16

    Gyeonggi-do, South Korea

  • Eisai Site #4

    Gyeonggi-do, South Korea

  • Eisai Site #11

    Gyeongnam, South Korea

  • Eisai Site #18

    Jungnam, South Korea

  • Eisai Site #7

    Jungnam, South Korea

  • Eisai Site #10

    Seoul, South Korea

  • Eisai Site #12

    Seoul, South Korea

  • Eisai Site #14

    Seoul, South Korea

  • Eisai Site #17

    Seoul, South Korea

  • Eisai Site #19

    Seoul, South Korea

  • Eisai Site #1

    Seoul, South Korea

  • Eisai Site #3

    Seoul, South Korea

  • Eisai Site #5

    Seoul, South Korea

  • Eisai Site #9

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.